Taken together, as selective partial PPARγ agonists, BTZD derivatives 1a, 1i and 3a improved not only the homeostasis of glucose metabolism, but also that of the lipid metabolism, suggesting that these compounds are very promising pharmacological agents by selectively targeting PPARγ for further development in the clinical treatment of T2D. This evidence concerns the gene PPARG and type 2 diabetes mellitus.